Reverse Merger - Summary of Pro Forma Results of Operation (Detail) - OncoGenex Pharmaceuticals, Inc [Member] - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2018 |
Jun. 30, 2017 |
Jun. 30, 2018 |
Jun. 30, 2017 |
|
| Business Acquisition [Line Items] | ||||
| Net loss applicable to common shareholders | $ (4,747) | $ (3,163) | $ (7,769) | $ (6,637) |
| Net loss per share-basic and diluted | $ (3.10) | $ (11.50) | $ (5.59) | $ (24.08) |
| Weighted average shares | 1,529,532 | 275,093 | 1,389,209 | 275,612 |
| X | ||||||||||
- Definition Business acquisition pro forma earnings per share basic and diluted. No definition available.
|
| X | ||||||||||
- Definition Business acquisition pro forma weighted average shares. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|